Aurora's CBD Lozenge Partnership: Here's Where To Find The New Product
Aurora's CBD Lozenge Partnership: Here's Where To Find The New Product
Cogent manufactures, packages and labels the CBG lozenge, a novel dissolvable format and is easy to dose.Canadian medical cannabis company Aurora Cannabis Inc. (NASDAQ:ACB) (TSX:ACB) and Vectura Fertin Pharma, Inc., an innovator in wellness and healthcare, announced on Monday the launch of the newly developed Luo CBD lozenge.
加拿大医用大麻公司奥罗拉大麻公司（纳斯达克股票代码：ACB）（多伦多证券交易所股票代码：ACB）和健康和医疗保健领域的创新者Vectura Fertin Pharma, Inc. 周一宣布推出新开发的Luo CBD润喉糖。
What Happened
发生了什么
The product was developed by Vectura Fertin Pharma, and represents the company's first medical cannabis CBD lozenge to be introduced in Canada.
该产品由Vectura Fertin Pharma开发，是该公司在加拿大推出的第一款医用大麻CBD润喉糖。
The move follows the announced commercial collaboration between Vectura Fertin Pharma's subsidiary Cogent International and the Edmonton, Alberta-based company to leverage Aurora's Canadian medical cannabis patient platform.
此举是在Vectura Fertin Pharma的子公司Cogent International与这家总部位于艾伯塔省埃德蒙顿的公司宣布进行商业合作以利用Aurora的加拿大医用大麻患者平台之后采取的。
Cogent manufactures, packages and labels the CBG lozenge, a novel dissolvable format and is easy to dose.
Cogent 制造、包装和贴标 CBG 润喉糖，这是一种新型的可溶解形式，易于给药。
Read Also: Aurora Cannabis Shares Jump On Q1 FY25 Earnings, Global Medical Marijuana Yields Record Revenue Of $343M
另请阅读：Aurora Cannabis股价在25财年第一季度的收益上涨，全球医用大麻的收入创纪录的3.43亿美元
- Get Benzinga's exclusive analysis and the top news about the cannabis industry and markets daily in your inbox for free. Subscribe to our newsletter here. If you're serious about the business, you can't afford to miss out.
- 每天在收件箱中免费获取Benzinga的独家分析以及有关大麻行业和市场的热门新闻。在这里订阅我们的时事通讯。如果你认真对待这项业务，就不能错过这个机会。
Why It Matters
为什么重要
Through Aurora's patient platform, Cogent will gain access to patient feedback on the CBD lozenge, which will be used to validate the product proposition and build real-world patient data to inform future products.
通过Aurora的患者平台，Cogent将获得患者对CBD lozenge的反馈，该反馈将用于验证产品主张并建立真实的患者数据，为未来的产品提供信息。
"As the leading provider of medical cannabis in Canada, the launch of the newly developed Luo CBD lozenge on our platform is a significant and exciting milestone at the beginning of our strategic collaboration with Vectura Fertin Pharma," said Aurora CEO Miguel Martin. "We are committed to bringing innovative solutions to patients and this launch reinforces our position at the forefront of Canada's medical cannabis industry."
奥罗拉首席执行官米格尔·马丁表示：“作为加拿大领先的医用大麻供应商，我们在平台上推出新开发的Luo CBD润喉糖，这是我们与Vectura Fertin Pharma战略合作之初的一个重要而激动人心的里程碑。”“我们致力于为患者提供创新的解决方案，此次发布巩固了我们在加拿大医用大麻行业前沿的地位。”
What's Next
下一步是什么
The two companies are open to exploring opportunities regarding the potential commercialization of other Vectura Fertin Pharma medical cannabis products in Canada.
两家公司愿意探索加拿大其他Vectura Fertin Pharma医用大麻产品的潜在商业化机会。
ACB Price Action
ACB 价格走势
Aurora's shares traded 2.96% higher at $5.57 per share during the pre-market session on Monday morning.
在周一上午的盘前交易中，Aurora的股价上涨了2.96％，至每股5.57美元。
- NASDAQ Cannabis Titan, Aurora, Could Boost 31% Sales Surge With This New CBD Lozenge Partnership
- 纳斯达克大麻巨头奥罗拉可以通过这种新的CBD Lozenge合作伙伴关系将销售额增长31％
